Trump Psychedelics Order Pressures DEA on Psilocybin Rescheduling

The Drug Enforcement Administration faces mounting pressure to expedite a pending psilocybin rescheduling petition following President Trump's executive order directing federal agencies to streamline psychedelic medicine access. Legal representatives for a physician seeking to treat terminally ill patients with psilocybin have filed an updated notice demanding the agency accelerate its review process, citing the administration's clear policy directive as justification for immediate action.

The petition represents a critical test case for federal psychedelic policy under the new administration. Trump's executive order explicitly instructs regulatory agencies to remove barriers preventing legitimate medical use of psychedelic compounds, creating a favorable regulatory environment that advocates argue makes continued delays unjustifiable. The DEA's response will signal whether the agency aligns with the administration's pro-psychedelic medicine stance or maintains its historically restrictive approach.

Public psychedelic companies including Compass Pathways (NASDAQ: CMPS), ATAI Life Sciences (NASDAQ: ATAI), and MindMed (NASDAQ: MNMD) have struggled with regulatory uncertainty, with most trading significantly below their IPO valuations. A favorable DEA ruling on psilocybin rescheduling could catalyze sector-wide momentum by establishing precedent for other psychedelic compounds currently in clinical development. The companies have collectively invested hundreds of millions in clinical trials while awaiting clearer regulatory pathways.

The timing creates unique pressure on DEA administrators who must balance traditional drug scheduling criteria with explicit White House directives favoring psychedelic medicine access. Unlike cannabis rescheduling efforts that faced political headwinds, psychedelic medicine enjoys bipartisan support focused on treating PTSD, depression, and end-of-life anxiety. This political alignment increases the probability of favorable regulatory outcomes compared to previous scheduling petition attempts.

Investor attention now focuses on DEA response timelines and the potential for expedited review processes under the Trump directive. A positive ruling could trigger significant capital inflows into psychedelic biotechnology companies while establishing the regulatory framework necessary for commercial psychedelic medicine programs. The agency's handling of this petition will likely influence similar rescheduling efforts and determine whether the nascent psychedelic medicine sector can transition from research-stage investments to revenue-generating operations.